E. P. Evdoshenko

1.8k total citations
34 papers, 364 citations indexed

About

E. P. Evdoshenko is a scholar working on Pathology and Forensic Medicine, Neurology and Molecular Biology. According to data from OpenAlex, E. P. Evdoshenko has authored 34 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pathology and Forensic Medicine, 14 papers in Neurology and 8 papers in Molecular Biology. Recurrent topics in E. P. Evdoshenko's work include Multiple Sclerosis Research Studies (32 papers), Peripheral Neuropathies and Disorders (8 papers) and Polyomavirus and related diseases (6 papers). E. P. Evdoshenko is often cited by papers focused on Multiple Sclerosis Research Studies (32 papers), Peripheral Neuropathies and Disorders (8 papers) and Polyomavirus and related diseases (6 papers). E. P. Evdoshenko collaborates with scholars based in Russia, United States and Switzerland. E. P. Evdoshenko's co-authors include Gleb Makshakov, С. В. Лапин, В. Д. Назаров, Éric Thouvenot, Charlotte E. Teunissen, Gavin Giovannoni, Vittorio Martinelli, Giulio Disanto, Niklas Norgren and Ludwig Kappos and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

E. P. Evdoshenko

27 papers receiving 359 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. P. Evdoshenko Russia 8 265 153 73 71 65 34 364
Johanna Oechtering Switzerland 12 200 0.8× 115 0.8× 63 0.9× 86 1.2× 45 0.7× 22 358
Shrishti Saxena United States 12 252 1.0× 126 0.8× 53 0.7× 149 2.1× 84 1.3× 27 450
Vanessa Daccach Marques Brazil 14 330 1.2× 263 1.7× 87 1.2× 96 1.4× 44 0.7× 32 522
Wiebke Stark Germany 9 266 1.0× 127 0.8× 47 0.6× 43 0.6× 70 1.1× 13 353
Francisco Gascón Spain 13 338 1.3× 139 0.9× 63 0.9× 67 0.9× 99 1.5× 30 462
Carolina Rush Canada 8 252 1.0× 83 0.5× 49 0.7× 41 0.6× 85 1.3× 17 314
Yu Yi M. Wong Netherlands 10 375 1.4× 265 1.7× 111 1.5× 46 0.6× 47 0.7× 15 433
Elisabet Matas Spain 11 306 1.2× 128 0.8× 93 1.3× 64 0.9× 65 1.0× 23 419
M. Alba Mañé-Martínez Spain 7 205 0.8× 103 0.7× 48 0.7× 52 0.7× 46 0.7× 10 270
E Daniëlle van Pelt Netherlands 10 288 1.1× 224 1.5× 86 1.2× 47 0.7× 27 0.4× 16 366

Countries citing papers authored by E. P. Evdoshenko

Since Specialization
Citations

This map shows the geographic impact of E. P. Evdoshenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. P. Evdoshenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. P. Evdoshenko more than expected).

Fields of papers citing papers by E. P. Evdoshenko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. P. Evdoshenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. P. Evdoshenko. The network helps show where E. P. Evdoshenko may publish in the future.

Co-authorship network of co-authors of E. P. Evdoshenko

This figure shows the co-authorship network connecting the top 25 collaborators of E. P. Evdoshenko. A scholar is included among the top collaborators of E. P. Evdoshenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. P. Evdoshenko. E. P. Evdoshenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Попова, Е. В., et al.. (2024). Early use of cladribine tablets for relapsing-remitting multiple sclerosis: Expert opinion. Meditsinskiy sovet = Medical Council. 101–107.
2.
Vlasov, I. V., et al.. (2024). Neuromyelitis optica spectrum disorders, terminology and therapeutic issues: amended consensus opinion. Neurology neuropsychiatry Psychosomatics. 16(6). 134–143.
3.
4.
Evdoshenko, E. P., et al.. (2022). Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy. SHILAP Revista de lepidopterología. 14(6). 139–148. 4 indexed citations
5.
Evdoshenko, E. P., et al.. (2021). Validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in the Russian Population. Journal of the International Neuropsychological Society. 28(5). 503–510. 5 indexed citations
6.
7.
Totolyan, N. А., et al.. (2020). The effect of cardiovascular diseases on the course of multiple sclerosis (review of literature). SHILAP Revista de lepidopterología. 26(3). 31–42.
8.
Makshakov, Gleb, et al.. (2020). The Impact of Intracortical Lesions on Volumes of Subcortical Structures in Multiple Sclerosis. American Journal of Neuroradiology. 41(5). 804–808. 3 indexed citations
9.
10.
Totolyan, N. А., В. Д. Назаров, Gleb Makshakov, et al.. (2020). Actual issues of serum aquaporin-4 autoantibodies evaluation in the diagnostics of neuromyelitis optica spectrum disorders. S S Korsakov Journal of Neurology and Psychiatry. 120(7). 24–24. 4 indexed citations
11.
Makshakov, Gleb, et al.. (2020). Comorbidity of neuromyelitis optica spectrum disorder and systemic lupus erythematosus. S S Korsakov Journal of Neurology and Psychiatry. 120(7). 102–102. 2 indexed citations
12.
Evdoshenko, E. P., Е. В. Попова, С А Сиверцева, et al.. (2019). Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia. PLoS ONE. 14(5). e0217303–e0217303. 6 indexed citations
13.
Назаров, В. Д., et al.. (2019). Diagnostic significance of intrathecally synthesized immunoglobulins against neurotropic viruses (MRZ-reaction) in diagnosis of multiple sclerosis. SHILAP Revista de lepidopterología. 9(5-6). 703–712. 1 indexed citations
14.
Evdoshenko, E. P., N A Malkova, Odinak Mm, et al.. (2019). The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis. S S Korsakov Journal of Neurology and Psychiatry. 119(10). 110–110.
15.
Назаров, В. Д., Gleb Makshakov, С. В. Лапин, et al.. (2018). Concentrations of immunoglobulin free light chains in cerebrospinal fluid predict increased level of brain atrophy in multiple sclerosis. Immunologic Research. 66(6). 761–767. 10 indexed citations
16.
Makshakov, Gleb, В. Д. Назаров, N. А. Totolyan, et al.. (2017). The association of intrathecal production of immunoglobulin free light chains and progression of multiple sclerosis. S S Korsakov Journal of Neurology and Psychiatry. 117(10). 4–4. 2 indexed citations
17.
18.
Evdoshenko, E. P., И. П. Пронин, А. Н. Бойко, et al.. (2016). Recommendations on the algorithms for drug choice and risk management plan in the treatment of patients with remitting multiple sclerosis with natalizumab. S S Korsakov Journal of Neurology and Psychiatry. 116(10. Vyp. 2). 79–79. 6 indexed citations
19.
Disanto, Giulio, Rocco Adiutori, Ruth Dobson, et al.. (2015). Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology Neurosurgery & Psychiatry. 87(2). jnnp–2014. 118 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Johanna Oechtering Breakdown of academic impact, for papers by Shrishti Saxena Breakdown of academic impact, for papers by Vanessa Daccach Marques Breakdown of academic impact, for papers by Wiebke Stark Breakdown of academic impact, for papers by Francisco Gascón Breakdown of academic impact, for papers by Carolina Rush Breakdown of academic impact, for papers by Yu Yi M. Wong Breakdown of academic impact, for papers by Elisabet Matas Breakdown of academic impact, for papers by M. Alba Mañé-Martínez Breakdown of academic impact, for papers by E Daniëlle van Pelt
Rankless by CCL
2026